Feb 19, 2021
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split
Feb 11, 2021
China SXT Pharmaceuticals, Inc. Enters into Non-Binding LOI to Acquire Jiangsu Renji Pharmaceutical Chain Co., Ltd.
Sep 09, 2020
NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement
Mar 16, 2020
China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government
Jan 16, 2020
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
Jan 03, 2020
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
Sep 11, 2019
China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques
Aug 19, 2019
China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019
Aug 12, 2019
China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate
Jul 03, 2019
China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production
May 22, 2019
China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province
Apr 17, 2019
China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing
Apr 02, 2019
China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification
Mar 28, 2019
China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018
Jan 04, 2019
China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering
Jan 02, 2019
China SXT Pharmaceuticals, Inc. Announces First Closing of Initial Public Offering
Sep 28, 2018
China SXT Pharmaceuticals, Inc. Announces Effectiveness of Registration Statement on Form F-1 and Pricing the Initial Public Offering of its Ordinary Shares at $4.00 per Share